Skip to main content

Mid and South Essex Combined

Initial response from Basildon and Brentwood CCG (also Thurrock and Mid Essex)

FOI Request: FreeStyle Libre Glucose Monitoring Sensors
Our Reference Number: 1819416

Dear Mr Cahm,

I am writing to acknowledge receipt of your request under the Freedom of Information Act 2000 to NHS Basildon and Brentwood CCG on 13th March 2019. The information is currently being collated and a response will be sent to you no later than 20 working days. The deadline is calculated to be 12th April 2019.

If you have any queries regarding your request, please do not hesitate to contact the FOI team on this email address.

A reply from the Diabetes Clinic (15/3)

Dear Nick
Thank you for the letter. I will direct this to our team lead who will answer this when she is next in the office next week.
Hope that is ok.

and a second reply on 18/3:

Hi Nick,

Thank you for your letter. From a DSN point of view we are keen to prescribe. We are bound by our medicines management team and we are awaiting instructions of how and when we can prescribe. This to be in line with our STP.


Also to note this meds management team cover Basildon and Brentwood and Thurrock CCG. The STP we are part of also includes Castle Point and Rochford, Southend and Mid Essex.


Final Response from CCG (now with Policy Document)


We are currently implementing the National Guidance which NHSE published on March 19th 2019 and a new Value-based Commissioning Policy will be in place from 1st April 2019.   

From 1st April 2019, patients assessed by specialist teams as meeting the policy criteria will be able to access Freestyle Libre funded by the NHS, with the initial supply coming from the hospital and then prescribing by GPs once they have been authorised to prescribe by the specialists. 

The Policy document, patient agreement forms and FAQs will be available on the website from 1st April 2019.

The policy is published here: Updated Libre Policy Mid and South Essex STP

Comments

Anonymous said…
The first criteria used by the STP appears to be contrary to the national guidance in that they will only prescribe to ‘poorly controlled’ diabetics.
Is it possible to challenge them on this?
Nick said…
Yes, this has been challenged....the East of England in general have been so confused by their own Prescription Advisory Committee that it's embarrassing. The next push will come when the April prescribing data is released, in about a month's time.

Popular posts from this blog

The CCG Project!

In order to find out the situation around the country for Libre prescribing now that the national policy has been published, I have made the decision to contact many of them to find out their plans.  I have arbitrarily chosen to contact all English CCGs that in December 2018 prescribed Libre via Primary Care to less than 5% of their population (and one specific request from a group member).  I had hoped this would be a small list, but there are 135 CCGs on the list.  I may have bitten off more than I can chew, but I'm committed to doing this and feeding back.  It worked before and hopefully this level of scrutiny will bring similar results. Below is a screenshot of the base document I am sending to each of the CCGs - it has some fields that are merge fields, so don't worry about the brackets and codes in the document (I found a typo, which has now been corrected too) .  The major piece of work with respect to this is finding the right person to contact.  However, I have s

Abbott dX 2022 Barcelona - "Make it Count"

For the past four years I've been invited by Abbott to a conference bringing together people with diabetes from across Europe to discuss various topics.  The first year I was meant to attend, it was my 'man v horse' year (the horse won!), so was unable to attend and then the pandemic hit so two further dX's were held virtually.  I was fortunate to be asked to present at last year's session.  This year's event was back in-person and held in Barcelona, coinciding with the latter part of the ATTD conference.   At this point, I must make it very clear - Abbott invited me to the 2022 European Diabetes Exchange forum (dX), that took place in Barcelona.  I attended this two-day event to connect and interact with inspirational and influential people in the diabetes community.  Abbott paid for my ticket and accommodation. #InvitedbyAbbott.  This is formal and it needs to be - I have not been required to do anything by Abbott as a result of my attendance and I hope that m

July Update - CCGs Under Pressure!

The heat is unbearable in some parts, not only in the environment, but also hopefully the heat directed at the decision-makers in 'non-compliant' CCGs who are either refusing to accept that Libre is a revolutionary tool for many T1s or have agreed to fund, but then set crippling criteria. Latest Prescribing Data Progress in prescribing continues, with stabilisation in Scotland and a continuation of the steady rise in the other three countries of the UK.  The Wales May data should be out this week. As mentioned last month, the situation in Scotland is particularly promising and the excellent Edinburgh Centre for Endocrinology and the Scottish Health Technologies Group have published documents that should significantly help the Libre case.  These documents are based on the first six months of prescribing Libre. Healthcare Improvement Scotland Statement Flash Glucose Monitoring is associated with improved glycaemic control and quality of life in people with type 1 d